Immunotherapy With CD22 CAR T-cells for B-Cell Lymphoma, ALL and CLL

Conditions:   Leukemia;   Lymphoma Intervention:   Biological: :Anti-CD22-CAR Sponsors:   Kecellitics Biotech Company Ltd;   Hebei Yanda Ludaopei Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials